- RecruitingPHASE2
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
This study is testing a new medicine, deucravacitinib, for adults with specific genetic skin conditions that cause inflammation and blisters or scaly skin. It aims to see how well it works and if it's safe over 44 weeks.
For: Epidermolysis Bullosa Simplex · Ichthyosis · GenodermatosisFrance - RecruitingPHASE3
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
This study is looking at a new medicine, Deucravacitinib, for children and teenagers aged 5 to 17 with a type of arthritis called Juvenile Psoriatic Arthritis. We want to see if it helps reduce their symptoms, how safe it is, and how much medicine is in their body.
For: Juvenile Psoriatic ArthritisUnited States · Brazil · Bulgaria - Active not recruitingPHASE2
Vitiligo Treatment by Targeting TYK2 Mediated Responses
This study is testing a new medicine called deucravacitinib for vitiligo. It aims to see if it can stop vitiligo from spreading and help skin regain its colour, especially when combined with light therapy.
For: Vitiligo, GeneralizedFrance - Active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares how well it works against a dummy treatment (placebo) and an existing medicine called deucravacitinib.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
This study is looking at a new medicine called deucravacitinib for people with active psoriatic arthritis who haven't tried certain other strong medicines for their condition before. It aims to see how well it works and if it's safe.
For: Psoriatic ArthritisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
This study is testing a new medicine called JNJ-77242113 for people with moderate to severe plaque psoriasis. Researchers want to see if it works better than a dummy treatment or another existing medicine.
For: Plaque PsoriasisUnited States · Australia · Brazil - RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
For: Plaque PsoriasisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
This study is testing a new medicine, Deucravacitinib, for adults with an active form of Sjögren's Syndrome. Researchers want to see if it's safe and effective compared to a dummy pill. It's a key step to finding better treatments for this autoimmune condition.
For: Sjögren's SyndromeUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
This study is testing a new medication called deucravacitinib for active psoriatic arthritis. It compares the new drug to a dummy pill to see if it helps people feel better and if it's safe. It's for people new to certain treatments or who have tried one specific type before.
For: Psoriatic ArthritisUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
This study is looking at a new medicine called deucravacitinib for children and teenagers aged 4 to 17 with moderate to severe plaque psoriasis. It aims to understand how much medicine is needed, if it works, and if it's safe to use.
For: Plaque PsoriasisArgentina · Australia · Brazil - Active not recruitingPHASE3
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
This study is looking at a new medicine called deucravacitinib to see if it's safe and helps people with a type of lupus called Systemic Lupus Erythematosus (SLE). It compares the new medicine to a dummy pill (placebo).
For: Systemic Lupus ErythematosusUnited States · Argentina · Australia